RoosterBio
@RoosterBio
Followers
2K
Following
2K
Statuses
6K
Accelerating hMSC & Exosome Product & Process Development to Fuel the Rapid Implementation of Scalable Advanced Therapies.
Frederick, MD
Joined April 2013
Achieve 10-fold #exosome yields with AgentV™-DSP, a powerful downstream processing solution. This chemically defined reagent solves filtration problems by breaking up biological components in conditioned media to prevent filter fouling & particle loss. ➡️
1
2
4
📘MISEV offers consensus-driven recommendations that enable extracellular vesicle researchers to design robust experiments, interpret results confidently, and ensure reproducibility. This allows EV-based discoveries to advance with clarity and credibility.
0
0
2
📢 Last call to join RoosterBio's webinar this Wednesday for an in-depth discussion on AgentV™-DSP and how to achieve up to 10X exosome yield. Register here➡️
🗓️ AgentV™-DSP is a solution specifically designed to overcome downstream process-related particle loss by addressing filtration problems. The result is 40-70% particle recovery and up to 10X increase in particle yield. Learn more in our upcoming webinar:
0
0
0
A key component to understanding the potential of extracellular vesicles is through analytical characterization and bioactivity assays. Our Exosome Analytics Packages now offer more options so you have all the information you need to know about your EVs.⤵️
0
0
3
📑This study by @KEnglishLab @MaynoothUni investigates how mesenchymal stromal cells inhibit pro-inflammatory effects of palmitate-induced innate training in macrophages, highlighting MSCs' potential as a therapeutic tool to control chronic inflammation.➡️
0
1
4
🗓️ AgentV™-DSP is a solution specifically designed to overcome downstream process-related particle loss by addressing filtration problems. The result is 40-70% particle recovery and up to 10X increase in particle yield. Learn more in our upcoming webinar:
0
0
0
📚 Every year, more groundbreaking work is published citing RoosterBio products and expertise. 2024 was the most prolific year yet for our research community's publication of peer-reviewed articles, pre-prints, theses, and other scientific literature.⤵️
0
0
1
💡 In 2024, more than 800 unique authors cited RoosterBio products or expertise in more than 80 published scientific resources. Our latest blog is an analysis of this growing list of "RoosterPubs" and what can be gleaned from its topics and trends.⤵️
0
0
2
In this blog, we discuss AgentV™-DSP, a solution to significantly improve exosome yield by economizing the downstream process. Learn how AgentV can be a valuable tool to make therapeutic EVs more affordable and broaden the scope of clinical applications.⤵️
0
0
0
RT @StemCellMarket: Introducing AgentV: Scalable Solution for 10X Exosome Yield @RoosterBio developed AgentV™-DSP…
0
1
0
📘 @KEnglishLab's team @MaynoothUni used MIF protein to enhance MSCs, boosting release of VEGF, a molecule aiding lung repair through angiogenesis and other activities. RoosterBio is proud to have contributed MSCs to support this groundbreaking research.
0
1
6
🗓️ Join our webinar on Wednesday, Feb. 12th at 11:00 am (ET) for an in-depth discussion on AgentV™-DSP, a solution specifically designed to address filtration problems by preventing filter fouling during downstream processing of exosomes. Register here:
0
0
1
What makes a good extracellular vesicle? At RoosterBio, we focus on Upstream Manufacturing and Downstream Processing to control factors that define EV therapeutics while using analytical characterization to monitor CQAs during production. Learn more here⤵️
0
0
1
📙 In the fight against cancer, MSCs can suppress tumor growth & mitigate treatment side effects but can also contribute to tumor microenvironments. With new molecular technologies, this engineerable therapy platform can still be a useful anti-cancer tool.
0
0
0
Using exosomes from human umbilical cord MSCs, the therapy enhanced estrogen production and receptor sensitivity in ovarian tissues, improved cellular proliferation, & reduced apoptosis. RoosterBio is proud to of helped supply cellular materials and media for this important work!
0
0
0
📊 To understand the potential of exosomes, well-designed analytical characterization and assays must be used. This study qualifies an MSC-EV CD73 bioactivity assay in line with established guidelines for linearity, specificity, accuracy, and precision.
0
0
0
🏙️ Join the RoosterBio team at @Phacilitate's Advanced Therapies Week on January 20-23 in Dallas, Texas. Visit Booth 649 to connect with our leadership and industry experts. We hope to see you there! #ATW25
0
1
1
🏆 RoosterBio's 2024 Development Award received a record number of applications from researchers advocating for novel studies in MSC and #exosome technology! We’re proud to announce a total of 13 award winners this year and their work. Congratulations all!
0
0
1
1️⃣ CD73: A Team Player Caught in the “AKT” of Wound Healing & Cell Survival via MSC Exosomes?
0
0
0
3️⃣ The Immortal Question: Can MSCs Be “Like a Cell Line But Not a Cell Line?”
1
0
0